Document is current
Any future updates will be listed below
-
Authors
Sigström, Robert https://orcid.org/0000-0003-1505-1532
Göteson, Andreas https://orcid.org/0000-0001-6118-6054
Joas, Erik
Pålsson, Erik
Liberg, Benny
Nordenskjöld, Axel https://orcid.org/0000-0001-7454-3065
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Landén, Mikael https://orcid.org/0000-0002-4496-6451
-
Funding
Funding for this research was provided by:
Fredrik och Ingrid Thurings Stiftelse (2019-00478)
Sahlgrenska Universitetssjukhuset (ALFGBG-942684, ALFGBG-715986, ALFGBG-965240, ALFGBG-71320, ALFGBG-965444)
Vetenskapsrådet (2017-00915, 2022-00732, 2019-02397, 2022-01643)
Alzheimerfonden (AF-930351, AF-939721, AF-968270)
EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236, JPND2021-00694)
Alzheimer's Association (ZEN-21-848495, SG-23-1038904 QC, ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C)
Alzheimer's Association
EC | Horizon 2020 Framework Programme (101053962, 860197)
Hjärnfonden (FO2022-0270)
Alzheimer's Drug Discovery Foundation (201809-2016862)
Alzheimer's Association
Alzheimer's Association
Alzheimer's Association
UK Dementia Research Institute at UCL (UKDRI-1003).
Stiftelsen för Strategisk Forskning (KF10-0039)
Wenner-Gren Foundation (SSv2019-0008)
- License Information
-
More Information
Article History
Received: 11 March 2024
Revised: 24 September 2024
Accepted: 26 September 2024
First Online: 3 October 2024
Competing interests
: AG, AN, EP and BL report no biomedical financial interests or potential conflicts of interest. RS reports that he has received honoraria from the Swedish Medical Products Agency outside the area of this research. EJ is currently employed at IQVIA, Mölndal, Sweden. KB reports that he has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ reports that he has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the submitted work. ML reports that he has received lecture honoraria from Lundbeck pharmaceutical outside the area of this research.
